Acquired perforating dermatosis

Source: Wikipedia, the free encyclopedia.
Acquired perforating dermatosis
Other namesAcquired perforating collagenosis
SpecialtyDermatology

Acquired perforating dermatosis is clinically and histopathologically similar to perforating folliculitis, also associated with chronic kidney failure, with or without hemodialysis or peritoneal dialysis, and/or diabetes mellitus, but not identical to Kyrle disease.[1][2]: 1462 

Signs and symptoms

On the hair-bearing limbs of adults, acquired perforating dermatosis typically manifests as extremely itchy follicular hyperkeratotic papules, which can occasionally become umbilicated. There may also be widespread papules.[3]

Causes

It is common for acquired perforating dermatosis to be linked to either renal failure, diabetes mellitus, or both.[3] Ten percent or so of dialysis patients develop acquired perforating dermatosis.[4] Additionally, it is sporadically linked to HIV, malignancy, hypothyroidism, and liver disease.[5]

Diagnosis

The patient's medical history, the lesions' clinical appearance, and, most importantly, histopathology with the identification of typical histological characteristics are all important in the diagnosis of acquired perforating dermatosis.[6] Bright white clouds and structureless grey areas are visible on dermatoscopy during acquired perforating dermatosis, and these features may help differentiate the condition from prurigo nodularis.[7]

Treatment

Since koebnerization can aggravate perforating disorders, treatment may focus on reducing pruritus. The majority of treatment approaches, such as topical or intralesional corticosteroids and oral or topical retinoids, are backed by anecdotal evidence. For pruritus, phototherapy (broad-band or narrow-band UVB, or psoralen plus UVA) may be beneficial. Other strategies include destructive techniques like cryotherapy, laser therapy, and surgical debridement, as well as the use of antibiotics like doxycycline.[3]

See also

References

  1. ^ Freedberg, et al. (2003). Fitzpatrick's Dermatology in General Medicine. (6th ed.). Page 540. McGraw-Hill. ISBN 0-07-138076-0.
  2. ^ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
  3. ^ a b c Lynde, C. B.; Pratt, M. D. (August 17, 2009). "Acquired perforating dermatosis: association with diabetes and renal failure". Canadian Medical Association Journal. 181 (9). CMA Joule Inc.: 615. doi:10.1503/cmaj.082013. ISSN 0820-3946. PMC 2764758. PMID 19687103.
  4. ^ Morton, C.A.; Henderson, I.S.; Jones, M.C.; Lowe, J.G. (1996). "Acquired perforating dermatosis in a British dialysis population". British Journal of Dermatology. 135 (5): 671–677. doi:10.1046/j.1365-2133.1996.d01-1062.x. PMID 8977664. S2CID 40685501.
  5. ^ Saray, Y; Seçkin, D; Bilezikçi, B (May 5, 2006). "Acquired perforating dermatosis: clinicopathological features in twenty-two cases". Journal of the European Academy of Dermatology and Venereology. 20 (6). Wiley: 679–688. doi:10.1111/j.1468-3083.2006.01571.x. ISSN 0926-9959. PMID 16836495. S2CID 19794920.
  6. ^ Harbaoui, Sarra; Litaiem, Noureddine (February 13, 2023). "Acquired Perforating Dermatosis". StatPearls Publishing. PMID 30969537. Retrieved February 1, 2024.
  7. ^ García-Malinis, A.J.; del Valle Sánchez, E.; Sánchez-Salas, M.P.; del Prado, E.; Coscojuela, C.; Gilaberte, Y. (April 10, 2017). "Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment". Journal of the European Academy of Dermatology and Venereology. 31 (10). Wiley: 1757–1763. doi:10.1111/jdv.14220. ISSN 0926-9959. PMID 28300323. S2CID 5319226.

Further reading

External links